[PHARMANIAGA BHD：印度尼西亚部门的需求增加]
1Q20 vs 1Q19:
截至2020年3月31日的第一季度，集团的收入增加到8.2亿令吉，较去年同期的7.86亿令吉增长4.3％。这主要是由于印度尼西亚部门的需求增加。该集团录得3100万令吉的税前利润（PBT），较去年同期增长2.1％。
因此，这季度的税后利润（PAT）增长14.1％至2200万令吉，而去年同期为2000万令吉。在政府医院的强劲贡献以及较低的运营成本的推动下，物流与分销部门的PBT达到了2300万令吉，比去年同期的1300万令吉提高了82.9％。
制造部公布了900万令吉的PBT，其收入为6,800万令吉，这与政府医院的订购趋势相符。在新产品的推出和持续的国际扩张以及通过其合同制造业务提高产能利用率的推动下，该部门继续保持乐观的前景。印尼部门录得3万令吉的亏损。
1Q20 vs 4Q19：
与前一季度相比，该集团第一季度的收入显着增加至8.2亿令吉。这主要归因于马来西亚和印度尼西亚政府和私立医院的需求增加。该集团公布3,100万令吉的PBT，相比前一季的2亿3千800万令吉的亏损。因此，这季度的PAT增至2200万令吉，相比前一季度的赤字为1亿7900万令吉。
前景：
该集团能够在今年第一季度取得可观的业绩。由于医疗保健部门竭尽全力防止病毒的进一步传播，政府宣布的各种经济刺激方案和与Covid-19相关的举措将有助于满足医疗保健从业者的需求，并提供急需的资金和支持。
作为领先的制药商，Pharmaniaga意识到了自己在关键时期的作用。该集团致力于履行与卫生部（MOH）的合同，向MOH设施提供药品和医疗用品，并向MOH提供物流和分销服务。为此，为确保可持续增长，发马将继续提高制造和运营效率，并扩大研发能力，以探索发展业务（包括印度尼西亚业务）的新途径。
-----------------------------
James Ng Stock Pick Performance:
Since Recommended Return:
a) FRONTKN (FRONTKEN CORP BHD), recommended on 12 Aug 18, initial price was RM0.715, rose to RM3.32 (dividend RM0.04) in 1 year 11 months 3 days, total return is 369.9%
b) TOPGLOV (TOP GLOVE CORP BHD), recommended on 1 July 18, initial price was RM12.14, rose to RM43.60 (adjusted)(dividend RM0.52) in 2 Years 14 days, total return is 263.4%
c) MI (MI TECHNOVATION BERHAD), recommended on 2 Jun 19, initial price was RM1.67, rose to RM5.01 (adjusted)(dividend RM0.055) in 1 Year 1 month 13 days, total return is 203.3%
d) OPENSYS (OPENSYS M BHD), recommended on 24 May 20, initial price was RM0.355, rose to RM0.765 in 1 month 21 days, total return is 115.5%
e) KKB (KKB ENGINEERING BHD), recommended on 1 Jul 18, initial price was RM0.795, rose to RM1.65 (dividend RM0.04) in 2 Years 14 days, total return is 112.6%
f) JAKS (JAKS RESOURCES BHD), recommended on 20 Jan 19, initial price was RM0.575, rose to RM0.875 in 1 year 5 months 24 days, total return is 52.2%
g) PWROOT (POWER ROOT BHD), recommended on 7 Oct 18, initial price was RM1.59, rose to RM2.18 (dividend RM0.188) in 1 Year 9 months 8 days, total return is 48.9%
我希望将我的策略分享给读者，希望他们在阅读后能够表现出色。我正在使用基本面分析（Fundamental Analysis）：
预计公司每年的增长率必须> 14％
我想说服读者学习基本面分析FA以便能从股市赚钱。
我为想从马来西亚股票市场赚钱的读者提供STOCK PICK服务。想订阅我的邮件以从股票市场获取良好回报的人，可以通过jamesngshare@gmail.com 或我的FB页面与我联系。
Whatsapp : 011 - 15852043
Facebook Group: https://www.facebook.com/groups/jamesinvesting
这个是我的TELEGRAM Group链接，大家可以在这个Group获知何时做Fb live: https://t.me/joinchat/LhwHNhdU1fDgxrSafTrTiw
请大家来Follow James的Instagram，获取最新的资讯：jamesnginvest
这个分享纯属讨论以及领域的分析，买或卖自负。请Like和Share这个post。最终决定永远是你的，谢谢。
James Ng
---------------------------
[PHARMANIAGA BHD: stronger demand from the Indonesia Division]
1Q20 vs 1Q19:
For the first quarter ended 31 March 2020, the Group delivered an improved revenue of RM820 million, up by 4.3% compared with RM786 million in the previous year’s corresponding quarter. This was primarily due to stronger demand from the Indonesia Division. The Group registered a profit before zakat and taxation (PBT) of RM31 million, reflecting a growth of 2.1% compared with last year’s corresponding quarter.
Accordingly, profit after tax (PAT) for the quarter under review grew by 14.1% to RM22 million, compared with RM20 million in the same quarter last year. The Logistics and Distribution Division turned in a higher PBT of RM23 million, up by 82.9% compared with RM13 million in the same quarter last year, driven by stronger contributions from Government hospitals as well as lower operating costs.
The Manufacturing Division posted a PBT of RM9 million on the back of a revenue of RM68 million, in line with order trends from Government hospitals. The Division continues to hold positive prospects, propelled by launches of new products and ongoing international expansion, coupled with increased capacity utilisation via its contract manufacturing business. The Indonesia Division recorded a deficit of RM0.03 million.
1Q20 vs 4Q19:
In comparison with the immediate preceding quarter, the Group’s revenue increased significantly to RM820 million for the first quarter. This was primarily attributable to stronger demand from Government and private hospitals in Malaysia and Indonesia. This saw the Group post a PBT of RM31 million compared with a deficit of RM238 million in the immediate preceding quarter. Accordingly, PAT for the quarter under review increased to RM22 million, compared with a deficit of RM179 million in the immediate preceding quarter.
Prospects:
The Group was able to deliver solid results in the first quarter of the year. As the healthcare sector does its utmost to prevent the further spread of this virus, the various economic stimulus packages and Covid-19 related initiatives announced by the Government will help to address the needs of healthcare practitioners, providing much-needed funds and support.
As a leading pharmaceutical manufacturer, Pharmaniaga is conscious of its role during this critical time. The Group is dedicated to fulfilling its contract with the Ministry of Health (MOH) for the provision of medicines and medical supplies to MOH facilities, as well as logistics and distribution services to MOH. In tandem with this, to ensure sustainable growth, the Group continues to enhance manufacturing and operational efficiencies and expand its research and development capabilities to explore new avenues to grow its business, including for its Indonesian operations.
--------------------------------------------------------------------------
I wish to share my strategy to readers, hope that they can perform well after reading this. I am using Fundamental Analysis:
the forecasted growth of a company must > 14% per year
I wish to convince readers to learn FA in order to make money from stock market.
I am providing STOCK PICK SERVICE for readers who want to make money from Malaysian stock market. Those who want to subscribe to my mailing list to achieve a good return from stock market, you can contact me at jamesngshare@gmail.com or PM me in my FB page.
This sharing is purely a discussion and analysis of the sector, buying or selling at your own risk. Please Like and Share this post. Final decision is always yours, thank you.
James Ng
https://klse.i3investor.com/blogs/general/2020-07-16-story-h1510571585.jsp
